CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 62 enrolled
Drug / intervention
dexmedetomidine +1 moredrug
Likely dose
dexmedetomidine 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01557270
NCT01557270Phase 3Completed
CompareCT.gov

The Efficacy and Safety of Dexmedetomidine as an Additive to Ropivacaine for Interscalene Brachial Plexus Blocks for Shoulder Surgery

Prof. Peter Gerner, M.D.·interventional·Posted Mar 19, 2012·Updated Dec 4, 2012

In Brief

A Phase 3 clinical trial evaluating dexmedetomidine and saline for Drug Safety and Self Efficacy. Completed, enrolled 62 participants across 1 site.

Detailed Summary

The purpose of this study is to test the efficacy and safety of dexmedetomidine added to ropivacaine in patients undergoing shoulder surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug Safety, Self Efficacy
CountriesAustria
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 19, 2012
Enrollment StartMar 1, 2012
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.3 years ago

Interventions

dexmedetomidinedrug

ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application

salinedrug

ropivacaine + saline placebo, single shot perineural application